Innate Responses
August 28, 2019
Can the innate immune system be reprogrammed to fight cancer? Inmune Bio believes the answer is yes.
1 min read
August 2019
Welcome to the August issue where, in our cover feature, we dive into the “outsourcing dilemma:” should you opt for a one-stop shop or specialist supply chain? Upfront examines current trends in US drug pricing and the potential of the innate immune system in the fight against cancer. Steve Arlington makes the case for maintaining links across borders, in In My View; while Best Practice outlines the steps to successfully bringing an advanced medicine to market. NextGen is skeptical about blockchain and dives into the story behind the UK’s CPI. And finally, we Sit Down With Adrian Woolfson, Vice President of Research and Development, Sangamo Therapeutics.
How to Find Your Secret Source
August 28, 2019
The complexity and scope of tasks within the (bio)pharma industry lend themselves to outsourcing – especially for small companies – but finding the right partner can be daunting. Do you opt for individual suppliers to form a specialist supply chain? Or do you choose the convenience of a one-stop shop? Here, we present perspectives generated at a Bio Integrates panel discussion.
1 min read
Celebrating Young Talent
August 27, 2019
Georg Winter wins the Young European Investigator award for his work on undruggable targets.
1 min read
Doing it For the Kids
August 26, 2019
Pfizer aims to improve pediatric clinical trials with increased investment.
1 min read
Full SPaeDD Ahead
August 21, 2019
Advances in pediatric drug development have been slow. We can do better if we collaborate.
1 min read
The Interface Between Art and Science
August 20, 2019
Sitting Down With… Adrian Woolfson, Executive Vice President of Research and Development, Sangamo Therapeutics, Brisbane, California.
1 min read
Advanced Medicines: Making it to Market
August 19, 2019
We’ve learned a number of lessons when it comes to developing and manufacturing cell therapies, including the importance of keeping our eyes on the end goal of commercial manufacturing – even at the earliest stages.
1 min read
Judging the New Kid on the Block
August 14, 2019
Can blockchain truly make a difference? Or is the novelty of the ledger technology its main selling point?
1 min read
The Phoenix of Process Innovation
August 14, 2019
Out of the ashes of the UK’s former largest chemical manufacturer, a not-for-profit company dedicated to de-risking innovation has risen. This is the story behind CPI.
1 min read
We Must Focus on Science, Not Geography
July 29, 2019
In times of political and social upheaval, maintaining our links across borders and working closely together is more important than ever.
0 min read
Born to Be Manufactured
July 26, 2019
Tablets are the preferred dosage form for both patients and drug manufacturers; the tableting process is well established and cost-effective, but the science and engineering go deeper than you might expect. A number of aspects must be considered to design a tablet that is well suited for commercial manufacture.
0 min read
